Key Stats | |
---|---|
Open | $8.02 |
Prev. Close | $8.26 |
EPS | -1.15 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $4.97B |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 7.67 | 8.14 |
52 Week Range | 1.25 | 10.53 |
Ratios | |
---|---|
P/B Ratio | 0.00 |
Revenue | - |
Operating M. % | -60,792.80% |
Earnings | $0.00 |
Earnings Growth % | -39.75% |
EBITDA Margin % | - |
ROE % | 0.00% |
EPS | -1.15 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
All Score 66 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
IBRX | MARKET | |
---|---|---|
Value | 38 | 37 |
Quality | 46 | 40 |
Ownership | 37 | 17 |
Growth | 76 | 46 |
Dividends | - | 37 |
ImmunityBio's Price growth average in the last 3 years of 10.42% is great compared to market average of 7.88%. This indicates IBRX could be a good value stock.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
The current price per share for ImmunityBio (IBRX) is $7.92. The stock has seen a price change of -$0.34 recently, indicating a -4.12% change. This reflects the stock's recent market performance and investor sentiment.
For ImmunityBio (IBRX), the 52-week high is $10.53, which is 32.95% from the current price. The 52-week low is $1.25, the current price is 533.6% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
ImmunityBio (IBRX) has shown an average price growth of 0.41% over the past three years. It has received a score of 45 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ImmunityBio as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
As of the latest data, ImmunityBio (IBRX) has a year-to-date price change of 51.15%. Over the past month, the stock has experienced a price change of 28.36%. Over the last three months, the change has been 91.3%. Over the past six months, the figure is 118.18%.
ImmunityBio (IBRX) has a net income of -$583.2M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -60.79K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$361.36M. Furthermore, the EBITDA is -$342.85M.
ImmunityBio (IBRX) has a market capitalization of $4.98B. The average daily trading volume is 19.28M, indicating the stock's liquidity and investor engagement.
Global Smartphone Shipments Jump by 20 Million Units Year-over-Year in Q1 2024
Pixel 8a Unveiled: Google’s AI Revolution Goes Mainstream
Visa’s Quarterly Revenue Jumped by $800 Million YoY and Hit an All-Time High of $8.75 Billion
Samsung Overtakes Apple in Q1 2024 Mobile Phone Shipments with 20.8% Market Share
Financial Industry Plagued by Ransomware Attacks; 65% of Organizations Suffered Ransomware Damage in 2023
GPU Prices: H100 Resellers Raking in Over 3X Profits on Popular Online Marketplaces
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.